MLSS

Milestone Scientific Inc.

$0.29

-3.34%
SectorHealthcareIndustryMedical Instruments & SuppliesCountryUnited States

Milestone Scientific Inc., a biomedical technology company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical and dental use in the United States, China, and internationally. It operates through Dental and Medical segments. The company provides the Wand, a single use disposable handpiece device for dental procedures that require local anesthetic under the CompuDent and STA Single Tooth Anesthesia System names. It also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, the company provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications.

Source: Yahoo Finance
AI summary

Price & performance

1M-23.9%
3M-21.9%
YTD+5.0%
1Y-27.5%
52-week range—
Beta0.95
Full chart and returns against a benchmark

Q-Score

36/ 100

Quality against peers; 50 is the peer median.

Growth43
Risk45
Performance36
Valuation41
Profitability43
Leverage38
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$9M+4.0%
Net income-$5.7M
Net margin-63.8%-9.1 pts
Historical fundamentals

Red flags in filings

2active red flags
Going-concern doubtMar 31, 2026
Auditor changeMay 6, 2026
Filings, findings and the timeline

Revenue exposure

45%of revenue from outside the US
United States55%
Rest of World41%
China3%
Largest customer49%
Regions, segments, customers and suppliers

Valuation

MLSSIndustryP/E—49.36P/S2.813.73EV/EBITDA—23.12P/B7.623.92PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 12next report
EPS estimate$-0.01
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate